This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
HCA Healthcare's (HCA) Q3 Earnings Miss on High Expense Level
by Zacks Equity Research
HCA Healthcare's (HCA) Q3 results were hurt by an increase in salaries and benefits expenses. Management presently estimates 2023 EPS to be within $17.80-$18.50, compared with the prior-view of $17.70-$18.90 per share.
Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosted procedure sales.
Here's What Key Metrics Tell Us About Intuitive Surgical, Inc. (ISRG) Q3 Earnings
by Zacks Equity Research
The headline numbers for Intuitive Surgical, Inc. (ISRG) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Intuitive Surgical, Inc. (ISRG) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 3.55% and 1.37%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical (ISRG) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.
Why Intuitive Surgical, Inc. (ISRG) Could Beat Earnings Estimates Again
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Intuitive Surgical, Inc. (ISRG) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $295.68, denoting a +1.93% change from the preceding trading day.
Intuitive Surgical, Inc. (ISRG) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) closed at $294.98 in the latest trading session, marking a +0.92% move from the prior day.
Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Intuitive Surgical, Inc. (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors continue to remain optimistic about CVS Health (CVS) due to the new acquisitions and the strong execution of the pharmacy business.
Zimmer Biomet (ZBH) Gains From ROSA Sales Growth Amid FX Woes
by Zacks Equity Research
Zimmer Biomet (ZBH) plans to work on the overall shift of the company's legacy knee systems to a fully rounded-out Persona portfolio.
Abbott (ABT) Rides on Nutrition Recovery Amid Low Testing Sales
by Zacks Equity Research
Abbott's (ABT) Nutrition business has started showing signs of recovery since the beginning of 2023.
Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Intuitive Surgical, Inc. (ISRG) and Artivion (AORT) have performed compared to their sector so far this year.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors continue to remain optimistic about Hologic (HOLX), backed by the Breast Health business' performance and international execution.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are increasingly optimistic about Labcorp (LH) due to its progress in hospital partnerships.
Neogen (NEOG) Gains From Strong Segmental Sales, Innovation
by Zacks Equity Research
Within the biosecurity portfolio, Neogen (NEOG) continues to record solid growth in cleaners, disinfectants and rodenticides.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
STERIS' (STE) healthcare segment benefits from procedure recovery, boosting investors' optimism.
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
The rapid expansion of Align Technology's (ALGN) business in international markets remains a key growth driver.
Intuitive Surgical, Inc. (ISRG) Stock Moves -0.86%: What You Should Know
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) closed at $290.74 in the latest trading session, marking a -0.86% move from the prior day.
Henry Schein (HSIC) Gains From Strong Global Network Amid FX Woes
by Zacks Equity Research
Henry Schein's (HSIC) dental software business is progressing well despite a challenging business environment.
Terumo's (TRUMY) MicroVention Enters Transradial Access Space
by Zacks Equity Research
The SOFIA EX 5F Catheter by Terumo's (TRUMY) MicroVention boasts a new design to enhance trackability.
Charles River (CRL) Opens a RightSource Lab in Stevenage
by Zacks Equity Research
Charles River's (CRL) new RightSource facility is likely to provide services to the Stevenage advanced therapy biocluster.
Intuitive Surgical, Inc. (ISRG) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $293.25, moving +1.75% from the previous trading session.
ResMed (RMD) Gains From Mask Sales Amid Macro Headwinds
by Zacks Equity Research
ResMed's (RMD) respiratory care business continues to drive growth, courtesy of the adoption of bilevel and other non-invasive ventilator solutions worldwide.